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Abstract
Background: The maximal expiratory flow at 50 % of the forced vital capacity (MEF50) is the flow where half of
forced vital capacity (FVC) remains to be exhaled. A reduced MEF50 has been suggested as a surrogate marker of
small airways disease. The diagnostic and prognostic utility of this easy to assess spirometric variable in persons
with respiratory symptoms, but without COPD is unclear.
Methods: We used data from the UHFO-COPD cohort in which 405 community-dwelling persons aged 65 years or
over, and a general practitioner’s diagnosis of chronic obstructive pulmonary disease (COPD) underwent pulmonary
function testing and echocardiography. In total 161 patients had no COPD according to the spirometric GOLD
criteria. We considered MEF50 as reduced if < 60 % of predicted.
Results: Of the 161 patients without COPD (mean age 72 ± 5.7 years; 35 % male; follow-up 4.5 ± 1.1 years), 61 (37.9 %)
had a reduced MEF50. They were older, had more pack-years of smoking, more respiratory symptoms, and used more
frequently inhaled medication than the remaining 100 subjects. A reduced MEF50 was nearly twice as often associated
with newly detected heart failure (HF) at assessment (29.5 % vs. 15.6 %, p = 0.045). In age-and sex-adjusted Cox
regression analysis, a reduced MEF50 was significantly associated with episodes of acute bronchitis (hazard ratio 2.54
95 % confidence interval (1.26; 5.13) P = 0.009), and in trend with pneumonia (2.14 (0.98; 4.69) P = 0.06) and
hospitalizations for pulmonary reasons (2.28 (0.93; 5.62) P = 0.07).
Conclusions: In older community-dwelling persons with pulmonary symptoms but without COPD, a reduced MEF50
may help to uncover unrecognized HF, and identify those at a higher risk for episodes of acute bronchitis, pneumonia
and hospitalizations for pulmonary reasons. Echocardiography and close follow-up should be considered in these
patients.
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Background
The maximal expiratory flow at 50 % of the forced vital
capacity (MEF50) is the flow where half of forced vital
capacity (FVC) remains to be exhaled [1]. It corresponds
to the forced expiratory flow at 50 % (FEF50) and corre-
lates highly with the maximum mid-expiratory flow
(FEF25-75 %) [2]. As such, MEF50 indicates obstruction
of small airways and may be used as a surrogate of early
small airways disease defined by an abnormally low mid-
expiratory flow in the presence of normal forced expira-
tory volume in 1 second (FEV1), FVC, and FEV1/FVC
ratio [3].
The usefulness of forced expiratory flows to diag-
nose small airways disease is, however controversial,
as intra-individual variability is high, even in healthy
subjects [4, 5]. Especially in the presence of central
obstructive ventilatory disorders such as COPD or
asthma, forced expiratory flow parameters lack repro-
ducibility and do not correlate well with other vari-
ables related to airway obstruction (as forced vital
capacity, FVC and residual volume-total lung capacity
index, (RV/TLC) [6, 7]. However, in absence of cen-
tral obstructive disorders, e.g. in patients with symp-
toms suggestive of COPD but in whom COPD has
been excluded spirometrically, a low maximal expira-
tory flow and small airways disease may strongly sug-
gest an alternative diagnosis, e.g. primary bronchiolar
disorders (bronchiolitis) or interstitial lung diseases
with bronchiolar involvement [8]. Moreover, a low
maximum expiratory flow might also direct differen-
tial diagnosis towards a non-pulmonary condition
causing respiratory symptoms such as heart failure,
either known or latent [9].
The aim of our analysis was to assess the prevalence
and the potential prognostic value of a low post-dilatory
MEF50, in older community-dwelling individuals with
pulmonary symptoms of airways obstruction, but with-
out COPD.
We assessed the relation of a low post-dilatory MEF50
with hitherto unknown heart failure, first episode of ei-
ther acute bronchitis, pneumonia, hospitalizations for
pulmonary reason, or all-cause mortality.
Methods
Study design and population
We made use of a data set derived from a prospective
cohort study (UHFO-HF) investigating 405 patients aged
≥65 years with a clinical diagnosis of COPD in primary
care. Population and study characteristics have been de-
scribed in detail previously [10]. Patients clinically sus-
pect of COPD but without spirometrically verified
obstruction were recruited from 51 primary care practices
and assessed in the outpatient clinic of the University
Medical Center Utrecht, Netherlands. A standardized
clinical examination, extensive pulmonary function testing
(PFT), chest radiography, and echocardiography were per-
formed in all participants [10]. Exclusion criteria com-
prised an already established diagnosis of heart failure,
severe psychiatric disorder, immobility, and terminal ill-
ness with short life expectancy precluding study participa-
tion [10].
In 244 of 405 (60 %) patients from the original cohort
COPD defined as a post-bronchodilator ratio of FEV1/
FVC <0.7 according to the GOLD criteria could be spir-
ometrically verified [11].
The present analysis refers to the remaining 161 pa-
tients with exclusion of a COPD diagnosis in spirometry.
The study complied with the Declaration of Helsinki,
and the Medical Ethics Committee of the University
Medical Center Utrecht approved the study protocol. All
participants gave their written informed consent.
Missing values
In four patients post-bronchodilator MEF50 values were
missing. In these patients pre-bronchodilator measure-
ments were used (two subjects with a MEF50 < 60 %, and
two with a MEF50 > 60 % of predicted). Thus, the present
study analyzes 161 patients without COPD.
Pulmonary function tests and definition of low MEF50
Pre-and post-bronchodilator pulmonary function testing
was performed with a fixed-volume bodyplethysmograph
(Masterlab Jaeger, Würzburg, Germany). The post-
bronchodilator test was assessed 30 minutes after inhal-
ation of 40 μg of ipratropium bromide.
There are no published guidelines regarding normal
values for MEF50. We used 60 % of post-dilatory MEF50
predicted as cut-off in the presence of a post-dilatory
FEV1/FVC ≥ 0.7 for defining low MEF50 [6]. Following
the recommendations of the European Respiratory Soci-
ety we used age, gender, and height for the calculation of
the predicted values of all lung function parameters [12].
Blood test results
Laboratory results such as white blood cell count,
haemoglobin, haematocrit, and serum aminoterminal
pro-hormone B-type natriuretic peptide (NT-proBNP)
were measured as part of the study assessment.
Echocardiography and definition of heart failure
Echocardiography was performed by two experienced
cardiac sonographers using a Philips Sonos 5500 imaging
system (Andover, MA, USA) and interpreted by a single
cardiologist, who was blinded to clinical data [10]. Left
ventricular ejection fraction (LVEF) was derived using
Simpson’s biplane or, when not possible, by single plane
area–length method [13].
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Left atrial volume was calculated by the biplane area–
length method from apical four-and two-chamber views
and indexed to the body surface area [14]. Mitral inflow
and pulmonary venous inflow were measured with
pulsed-wave Doppler echocardiography. Tissue Doppler
was used to assess the sub-mitral movement of the sep-
tal wall, and a composite of abnormalities in diastolic
function was employed to define diastolic dysfunction
[15].
Presence or absence of heart failure was established by
an expert panel consisting of two cardiologists, a pulmo-
nologist, and a general practitioner using all available
diagnostic information, including echocardiography and
pulmonary function tests [10]. Heart failure was classi-
fied by the panel in line with the recommendations of
the ESC guidelines on heart failure. The definition re-
quired presence of signs and symptoms suggestive of
heart failure and additional criteria that led to the fol-
lowing subtypes: a) “heart failure with a reduced ejection
fraction” when LVEF was reduced (arbitrarily defined as
≤45 %); b) “heart failure with preserved ejection fraction”
when echocardiographically determined diastolic dys-
function was present and LVEF >45 %; of note, symp-
toms and/or signs should not, or insufficiently, be
explained by co-incident pulmonary disease; and c)
“right-sided heart failure” (cor pulmonale) when LVEF
was >45 %, and the calculated pulmonary artery pressure
>40 mmHg [10].
Follow-up and outcomes ascertainment
Patients included in the study were followed from April
2001 to June 2007 during a mean period of 4.3 (standard
deviation 1.1) years. The follow-up data collection mode
was described before [16]. In brief, the general practi-
tioner’s (GP) electronic medical files were scrutinized to
obtain information on patient’s drug prescription, pul-
monary hospitalizations and survival status. Acute bron-
chitis was defined as an episode with bronchial wheezing
and rhonchi for which the GP prescribed antibiotics
and/or pulse prednisolon for 7 to 10 days.
Most episodes of pneumonia were diagnosed clinically
by the GP and only occasionally confirmed by chest
X-ray or sputum culture.
Data analysis
Continuous data were expressed as mean (standard devi-
ation, SD) or median (quartiles). Group comparisons be-
tween patients with and without a MEF50 < 60 % of
predicted were performed using Fisher’s exact test or
Mann–Whitney U-test, as appropriate (Tables 1 and 2).
Correlations between MEF50 with other pulmonary func-
tion parameters were calculated with the Spearman rank
order correlation coefficient (r). The strength of the cor-
relation was graded using the following guide for the
absolute value of r: 0.00-0.19 very weak; 0.20-0.39 weak;
0.40-0.59 moderate; 0.60-0.79 strong; 0.80-1.0 very
strong.
Univariate, and age and sex adjusted multivariable
Cox regression models were calculated for different
outcomes (acute bronchitis, pulmonary hospitaliza-
tions, pneumonia, and all-cause mortality) and re-
ported as hazard ratios (HR) with 95 % confidence
intervals (CI). P values <0.05 were considered statisti-
cally significant. Data analysis was performed with
SPSS 21 (IBM, Munich, Germany).
Results
Demographics of the patients with COPD according to
the GOLD criteria
Patients excluded from our analysis (244 individuals with a
GOLD diagnosis of COPD) were more often male (68 vs.
35 %, P < 0.001), and slightly older (73 [70; 77]) vs. 72
[67; 76] years P = 0.016) than the 161 patients included. All
but one of the 243 patients with GOLD-COPD and avail-
able information on MEF had a post-dilatory MEF50 < 60 %
of predicted confirming that a MEF50 below the chosen
threshold is common in COPD.
Demographics of the patients without COPD according to
the GOLD criteria
Table 1 lists the baseline characteristics of the 161 indi-
viduals under study, stratified by MEF50 </≥ 60 % of pre-
dicted. Patients with a low MEF50 (38 %) were older, had
more pack-years of smoking, suffered more often from
respiratory complaints, used more often inhaled medica-
tion (especially anticholinergics), and had higher leucocyte
counts than subjects with a MEF50 ≥ 60 %. Twenty-two of
the 63 patients (35 %) with a low MEF50 < 60 % of pre-
dicted had a FEV1 and/or FVC % of predicted below
80 %. The remaining 41 participants (65 %) had normal
values of FEV1 and FVC % of predicted.
Correlation between MEF50 and other pulmonary function
test results
Patients with a low MEF50 had a normal total lung cap-
acity (TLC), while the carbon monoxide (CO) diffusion
capacity was lower than in those with a MEF50 ≥ 60 % of
predicted. Patients with a low MEF50 also had higher
levels of total resistance, higher residual volume (RV)
and larger RV/TLC ratio than subjects with a ‘normal’
MEF50 (Table 2). Reversibility of airway obstruction, de-
fined as an increase of FEV1 levels > 200 ml and >12 %
to baseline, did not differ between </≥ MEF50 60 % of
predicted.
Table 3 presents Spearman rank-order correlation co-
efficients for the association between MEF50 and other
continuous pulmonary function test parameters. MEF50
correlated moderately to strongly with all pulmonary
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function test results, except for TLC (no correlation)
and RV (very weak correlation).
Association of low expiratory flow with newly detected
heart failure
In total, N = 33 patients (20.5 %) were newly diagnosed
with heart failure; N = 16 with heart failure with reduced
ejection fraction, N = 17 with heart failure with pre-
served ejection fraction, and N = 0 isolated right-sided
heart failure. A MEF50 < 60 % was associated with a new
diagnosis of heart failure at the assessment: The inci-
dence of newly diagnosed heart failure was 29.5 % in
those with MEF50 < 60 % compared to 15.6 % in persons
with a MEF50 ≥ 60 % of predicted (P = 0.045, Table 1).
Patients with a novel diagnosis of heart failure also had
lower post-dilator MEF75 % of predicted (84 % [64; 103 %]
vs. 97 % [86; 119 %], P = 0.03) than the 128 patients without
heart failure, whereas peak expiratory flow and post-dilator
Table 1 Characteristics of 161 patients with a GP’s diagnosis of COPD, but with a post-dilatorory FEV1/FVC ratio > 0.7, divided in
those with MEF50 < vs ≥ 60 % of predicted
All, N = 161 MEF50 < 60 % of predicted, N = 63 MEF50≥ 60 % of predicted, N = 98 p-value
Demographics
Male sex, % 34.8 30.2 37.6 0.40
Age, years 72 (67; 76) 73 (69; 79) 71 (66; 74) 0.002
Pack years smoking, years 2.3 (0; 28) 10 (0; 38) 0.6 (0; 20) 0.026
Body mass index, kg/m2 27.0 (24.7; 30.0) 26.9 (24.7; 30.7) 27.1 (24.7; 29.7) 0.87
LVEF in % 60 (58; 60) 60 (56; 62) 60 (59; 60) 0.88
Systolic blood pressure, mmHg 154 (142; 164) 154 (144; 164) 153 (142; 165) 0.60
Comorbidities
Hypertension; % 53.4 46.0 46.9 1.0
Atrial fibrillation, % 5.0 3.2 6.1 0.48
Diabetes, % 9.9 6.3 12.2 0.29
A history of asthma, % 12.4 14.3 11.2 0.63
Heart failure, % 20.5 28.6 15.3 0.048
Obesity 24.8 28.6 22.4 0.45
Symptoms
Dyspnoea uphill, % 93.2 95.2 91.8 0.53
Dyspnoea while walking on level ground, % 43.5 58.7 33.7 0.002
Coughing >3 months, % 27.3 36.5 21.4 0.046
Wheezing, % 59 71.4 51.0 0.014
Phlegm production, % 42.9 49.2 38.8 0.20
Laboratory findings
Hemoglobin, mmol/l 8.9 (8.3; 9.4) 8.9 (8.3; 9.2) 9.0 (8.4; 9.6) 0.24
Leucocytes /nl 7.3 (6.1; 8.7) 7.6 (6.8; 9.5) 7.0 (5.9; 8.2) 0.004
C-reactive protein, mg/l 3 (3; 6) 3.0 (3.0; 7.0) 3.0 (3.0; 5.8) 0.24
NT-proBNP, mg/dl 14.3 (8.1; 25.5) 16.8 (10.1; 29.3) 13.9 (7.0; 24.9) 0.078
Pharmacotherapy
Diuretics 23.6 28.6 20.4 0.2
ACEi or ARB, % 23.6 25.4 22.4 0.71
Beta-blocker, % 13.7 11.1 15.3 0.49
Aspirin, % 23.0 27.0 20.4 0.34
Inhaled beta-2agonist, % 41.6 49.2 36.7 0.14
Inhaled anticholinergic, % 36 47.6 28.6 0.018
Inhaled corticosteroid, % 58.4 61.9 56.1 0.30
Chronic oral corticosteroid, % 1.9 4.8 0 0.058
Values are shown as median (quartiles) or percentages
Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; obesity was defined as a body mass index ≥ 30 kg/m2
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MEF25 % were not different between these two groups. Pa-
tients with heart failure had more often FEV1 values below
80 % of predicted than subjects without heart failure
(27 % vs. 12 %, P = 0.05). The corresponding FVC values
were also numerically but not statistically different (FVC
below 80 % of predicted 21 vs. 11 %, P = 0.15).
Association of low MEF50 with prognosis
During follow-up, 34 patients experienced acute bron-
chitis and 27 patients a pneumonia, 21 patients were
hospitalized for a pulmonary reason (pneumonia, bron-
chitis, acute exacerbation of newly diagnosed COPD), and
17 patients died (Table 4). In age-and sex-adjusted Cox re-
gression analysis, a low MEF50 was significantly associated
with acute bronchitis (2.54 (1.26; 5.13) P = 0.009) but not
with pneumonia (2.14 (0.98; 4.69) P = 0.06), hospitaliza-
tions (2.28 (0.93; 5.62) P = 0.07, Table 5) or death
(1.84 (0.68; 4.99) P = 0.23). If patients with heart fail-
ure (n = 33) were excluded from the analysis the as-
sociations became significant for all outcome
measures except total mortality (Table 5).
Discussion
In this retrospective analysis of 161 older
community-dwelling individuals with a clinical diag-
nosis of COPD but without spirometrically verified
airways obstruction, we found that low maximum
mid-expiratory flow (i.e., MEF50 < 60 % of predicted)
was prevalent in 38 %. These patients had increased
pulmonary resistance and residual volumes, and a
higher RV/TLC index than subjects with a MEF50
≥ 60 %. Further, a low MEF50 was associated with in-
cident heart failure and predicted a higher risk for
acute bronchitis during follow-up.
Small airways disease is frequently found in patients
with airways obstruction as asthma or COPD [6]. In the
present study we did not see differences in the prevalence
of low MEF50 in patients with and without a history of
asthma. However, since our patients were selected accord-
ing to a GP’s diagnosis of COPD, the prevalence of pa-
tients with a history of asthma was low (12 % in the total
cohort). Reduced MEF is a characteristic feature of COPD
[4]: in the original cohort of patients with verified COPD
(244/405, data not shown) according to the GOLD
Table 3 Correlation between MEF50 and other pulmonary function parameters
FEV1/ FVC FEV1 FVC Rtot TLC RV RV/TLC DLCO MEF25 % MEF75 % PEF
r 0.62** 0.64** 0.46** -0.63** 0.13 −0.18* −0.58** 0.50** 0.84** 0.76** 0.59**
Spearman’s correlation coefficients (r) between continuous values of MEF50 and other pulmonary function parameters (as % of predicted) with the Spearman’s
rank correlation test
* refers to p < 0.05 and **to p < 0.001
Table 2 Pulmonary function test results in patients with a MEF50 < vs ≥ 60 % of predicted
All, N = 161 MEF50 < 60 % of predicted, N = 63 MEF50≥ 60 % of predicted, N = 98 P value
Post-dilator FEV1/FVC, % 76 (74; 81) 74 (71; 76) 80 (76; 85) <0.001
FEV1, % of predicted 103 (89; 115) 85 (75; 102) 110 (101; 121) <0.001
FVC, % of predicted 105 (91; 120) 93 (80; 112) 112 (100; 125) <0.001
Post-dilator increase of FEV1 > 200 ml, % 13.7 17.5 11.2 0.35
Post-dilator increase of FEV1 > 200 ml and >12 %, % 11.8 14.3 10.2 0.46
Rtot, % of predicted 124 (86; 178) 165 (121; 213) 110 (76; 143) <0.001
TLC, % of predicted 105 (97; 114) 103 (93; 112) 107 (97; 116) 0.18
TLC < 80 % of predicted, % 3.1 3.1 3.3 0.99
RV, % of predicted 108 (96; 126) 112 (100; 141) 107 (93; 120) 0.025
RV/TLC, % 102 (93; 115) 114 (101; 132) 98 (90; 106) <0.001
DLCO, % of predicted 78 (67; 89) 70 (59; 80) 83 (75; 93) <0.001
MEF25, % of predicted 54 (38; 76) 38 (30; 46) 68 (54; 93) <0.001
MEF50, % of predicted 68 (49; 86) 47 (39; 55) 79 (70; 98) <0.001
MEF75, % of predicted 94 (74; 111) 75 (58; 91) 104 (91; 122) <0.001
PEF, % of predicted 104 (88; 121) 98 (73; 108) 111 (96; 129) <0.001
Data are shown as median (quartiles) or percentages. All pulmonary function test variables refer to post-dilatory values and are presented as percentage of
predicted or as percentages
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; Rtot, total resistance; TLC, total lung capacity; DLCO,
diffusion capacity of carbon monoxide; MEF maximum expiratory flow 25/50/75 % of the FVC remain to be exhaled; PEF peak expiratory flow
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criteria, a MEF50 < 60 % of predicted was detected in 242
out of 243 persons (data not shown). In the remaining pa-
tient, MEF values were not available. The prognostic cap-
acity of low MEF is thus not meaningful in patients with
established airways obstruction.
Lower MEF values may also be found in the ab-
sence of airways obstruction, in primary bronchiolar
disorders or interstitial lung disease, but also in sys-
temic inflammatory diseases such as rheumatoid
arthritis [8]. A low MEF is easily detectable with
spirometry and relates to inflammation of the small
non-cartilaginous bronchioles with an internal diam-
eter of <2 mm and may well be an indicator of small
airways disease or be considered as a precursor stage
of COPD [6, 17, 18]. However, to determine the
underlying pathophysiological substrate, histological
investigation of lung biopsies or high resolution
computer tomography scans would be needed, proce-
dures that are not part of the routine assessment in
clinical practice and thus were not available for this
study [8, 19].
Expiratory flow volumes have previously been pro-
posed as a tool for diagnosing extra-pulmonary restrict-
ive disease [9]. Heart failure is such a condition as
increased heart size and pulmonary congestion may sim-
ply reduce lung volumes [20]. In addition, pulmonary
fluid overload in heart failure may cause or aggravate ex-
ternal bronchial obstruction with subsequent comprom-
ise of FEV1 [20, 21]. Thus, clinically and spirometrically,
heart failure frequently mimics COPD. Indeed, in con-
gestive heart failure, it has been repeatedly be shown
that FEV1 values may be more reduced than corre-
sponding FVC values, yielding FEV1/FVC ratios <0.70 in
the absence of COPD [22, 23]. Importantly, this finding
(i.e., pseudo-COPD) is not reproducible when the same
individuals are re-assessed after recompensation under
euvolemic conditions, calling for a more conscious use
of spirometry in these cases [21, 24, 25]. Additionally,
expiratory flow measurements may be more susceptible
to heart failure than FEV1 or FEV1/FVC: in 29.5 % of
the cases with a MEF50 < 60 % of predicted, previously
unrecognized heart failure was detected. This is more
than three times as high as might be expected in the
general population aged > 65 years (estimated preva-
lence of heart failure in this age group 7-10 %) [26]
and also higher than the percentage of newly detected
cases of heart failure in the 244 patients with a
GOLD-COPD diagnosis (prevalence 21 %) from the ori-
ginal cohort [10, 27]. Further 18 out of 33 patients
(55 %) with previously unrecognized heart failure had
a MEF50 < 60 % predicted, whereas only 9 (27 %) had
a reduced FEV1 < 80 % predicted.
Although our study convincingly related a reduced
MEF50 to clinically relevant outcomes, we acknowledge
that the causality of these associations is not stringent.
Some studies found that MEF50 was below average in
subgroups of healthy never smokers [4, 5], or asymp-
tomatic subjects [28]. Further, higher body mass index
levels may attenuate MEF [29], but we observed no rela-
tion between body mass index levels and low MEF50
(Table 1).
Study limitations
The extensive pulmonary function testing with spir-
ometry, bodyplethysmography, and CO diffusion mea-
surements was performed only once at baseline, thus,
time-dependent effects could not be addressed. Be-
cause histological investigations or chest CT scans
Table 4 Number of pulmonary events and all-cause deaths during a mean follow up of 4.5 years in patients with and without
MEF50 < 60 % of predicted
All (N = 161) MEF50 < 60 % N = 63 MEF50≥ 60 % N = 98 P value
Episodes of acute bronchitis, N (%) 34 (21.1 %) 20 (31.7 %) 14 (14.3 %) 0.01
Pneumonia, N (%) 27 (16.8 %) 15 (23.8 %) 12 (12.2 %) 0.08
Hospitalization for pulmonary reason, N (%) 21 (13.0 %) 12 (19.2 %) 9 (9.2 %) 0.09
All-cause death, N (%) 17 (10.6 %) 10 (15.9 %) 7 (7.1 %) 0.11
Absolute numbers of clinically relevant outcome measures during follow-up. P value refers to Fishers exact test
Table 5 Prognostic utility of MEF50 < 60 % of predicted in patients without COPD
Acute bronchitis Pneumonia Hospitalization for pulmonary reasons Death
Model 1 2.53 (1.28; 5.02) P = 0.008 2.11 (0.99; 4.51) P = 0.054 2.24 (0.94; 5.31) P = 0.07 2.17 (0.83; 5.71) P = 0.11
Model 2 2.54 (1.26; 5.13) P = 0.009 2.14 (0.98; 4.69) P = 0.06 2.28 (0.93; 5.62) P = 0.07 1.84 (0.68; 4.99) P = 0.23
Model 3 3.04 (1.36; 6.79) P = 0.007 2.66 (1.10; 6.40) P = 0.03 3.86 (1.25; 11.9) P = 0.019 1.97 (0.52; 7.36) P = 0.32
Hazard ratios with 95 % confidence intervals from Cox proportional hazard regression are presented. Median follow-up was 4.6 years. MEF50 < 60 % of predicted
coded as “1”
Model 1: Unadjusted
Model 2: Adjusted for age and sex
Model 3: Adjusted for age and sex in the subgroup of 128 patients without heart failure
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were not available in the GP setting of the current
study, we were unable to assess small airways disease
on a more pathophysiological basis. Further restrictive
disorders might also account for MEF reduction. Pa-
tients with pulmonary restriction were not excluded
in this study however, the prevalence in total cohort
was low (3.1 %, N = 5) and there was no between
group difference between patients with and without a
MEF50 < 60 %.
Conclusions
In older community-dwelling patients with pulmonary
symptoms but without central airway obstruction a
low maximum MEF, easily obtained by spirometry,
showed clinical utility to identify patients with previ-
ously undiagnosed heart failure and patients at risk
for pulmonary events. Thus, MEF50 values should also
be evaluated when obtaining spirometry in persons
aged >65 years with shortness of breath.
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